Title: Trial of Steroids in Pediatric Acute Lung Injury/ARDS (SPALIT)

Accession Number: NCT01274260

Link to Dataset: https://clinicaltrials.gov/ct2/show/NCT01274260

Repository: ClinicalTrials.gov

Data Type(s): Clinical Trials

Experiment Type(s): Interventional

Organism(s): Homo sapiens

Summary: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are devastating disorders associated with lung inflammation, low oxygen levels and respiratory failure in children. Prevalence of ALI ranges from 2.2 to 12 per 100,000 children per year. Using these estimates, up to 9,000 children each year will develop ALI/ARDS, which may cause upto 2,000 deaths per year. Currently, there are no specific therapies directed against ARDS/ALI in children. In adult patients, use of steroids early in the course of ARDS appears promising. There are no published clinical trials examining the use of steroids for the treatment of ALI/ARDS in children.

Publication(s) associated with this dataset:

• Kimura D, Saravia J, Rovnaghi C, Meduri UG, Schwingshackl A, Cormier SA, Anand KJ. 2016. Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisolone: a framework for identifying plasma biomarkers related to clinicaloutcomes in pediatric ARDS. Front Pediatr 4:31. doi:10.3389/fped.2016.00031 PMID:27066464 PMCID:PMC4815896
• Schwingshackl A, Kimura D, Rovnaghi C, Saravia J, Cormier SA, Teng B, West AN, Meduri UG, Anand KJ. 2016. Regulation of inflammatory biomarkers by intravenous methylprednisolone in pediatric ARDS patients: results from a double-blind, placebo-controlled randomized pilot trial. Cytokine 77:63-71. doi:10.1016/j.cyto.2015.10.007 PMID:26545141 PMCID:PMC4666843